Latest news with #Qritive
Time of India
a day ago
- Health
- Time of India
Dr Lal PathLabs introduces AI integration in cancer diagnosis
Mumbai: Healthcare diagnostics provider Dr. Lal PathLabs has introduced deep learning-based artificial intelligence (AI) module to detect lymph node metastasis , including micrometastasis, in cancer cases. The technology, developed in collaboration with AI solution developer Qritive , was recently showcased at USCAP 2025, one of the world's leading pathology conferences. According to the company, QiAI Lymph Node Dx will help in improving the accurate identification of cancer spread to lymph nodes. The company also states that by detecting metastasis early, the tool can reduce the risk of cancer progressing to advanced stages and spreading to distant organs, which often lowers survival rates. The tool is further indicated to also assist in identifying micrometastases—tiny clusters of cancer cells in lymph nodes—that usually require considerable time and specialized tests to detect. Using deep learning to analyze digital slides, the tool can spot cancer cells, including single-cell metastases, with complete sensitivity and no false negatives, findings that have been confirmed through immunohistochemistry. It is indicated that the technology has been validated across multiple cancer types, including breast, colon, stomach, and esophageal cancers. 'The role of a pathologist is evolving rapidly, and we must evolve with it. Introducing AI into our diagnostic workflow is not just about adopting technology — it's about reimagining how we detect and respond to disease,' said Dr Vandana Lal, Executive Director, Dr Lal PathLab
Business Standard
2 days ago
- Health
- Business Standard
Dr. Lal PathLabs adopts AI-powered diagnostics for cancer detection
Dr. Lal PathLabs (DLPL) has become the first laboratory in the country to adopt a deep learning-based AI module to detect lymph node metastasis, including micrometastasis, in cancer cases. This cutting edge technology, validated in collaboration with Qritive, was showcased at USCAP 2025 one of the world's leading pathology conferences. Accurate identification of cancer spread to lymph nodes is vital in determining the stage and treatment path for patients. If the spread of cancer to the lymph nodes is left undetected, it can allow the disease to progress to later stages, increasing the risk of metastasis to distant organs and significantly reducing survival rates. Therefore, the identification of occult metastases in patients with early-stage cancer could have a substantial clinical impact on treatment planning and optimal therapy for patients with cancer.
&w=3840&q=100)
Business Standard
2 days ago
- Business
- Business Standard
Dr. Lal Path Labs rises 3% on adopting new AI cancer diagnostic tool
Dr. Lal Path Labs shares rose 3.2 per cent on Wednesday, August 20, 2025, logging an intra-day high at ₹3496.75 per share on BSE. At 11:37 AM, Dr. Lal Path Labs share price was trading 1.96 per cent higher at ₹3454.3 per share. In comparison, the Sensex was 0.14 per cent higher at 81,756.74. Why were Dr. Lal Path Labs shares in demand? The northward movement in the stock came after Dr. Lal Path Labs became the first laboratory in the country to adopt a deep learning-based AI module to detect lymph node metastasis, including micrometastasis, in cancer cases. This technology, validated in collaboration with Qritive, was showcased at USCAP 2025, one of the world's leading pathology conferences. Detecting micrometastases—tiny clusters of cancer cells in lymph nodes—usually takes a lot of time and special tests. The AI tool QiAI Lymph Node Dx changes that by using deep learning to quickly and accurately spot cancer cells on digital slides. Adding this technology to regular medical practice makes diagnosing cancer faster and more reliable. Accurate identification of cancer spread to lymph nodes is vital in determining the stage and treatment path for patients. If the spread of cancer to the lymph nodes is left undetected, it can allow the disease to progress to later stages, increasing the risk of metastasis to distant organs and significantly reducing survival rates. Therefore, the identification of occult metastases in patients with early-stage cancer could have a substantial clinical impact on treatment planning and optimal therapy for patients with cancer. The AI system was tested on digital slides from breast, colon, stomach, and esophageal cancer cases. It accurately detected single-cell and micrometastases that had been missed during manual reviews. These results were later validated through immunohistochemistry (IHC), confirming the system's reliability, according to the filing. About Dr. Lal Path Labs Dr. Lal Path Labs is a provider of diagnostic and related healthcare tests and services in India. Through its integrated, nationwide network, the Company offers patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis, and the prevention, monitoring, and treatment of disease and other health conditions. As of March 31, 2025, the company has 298 clinical laboratories (including National Reference Lab at Delhi, Regional Reference Lab at Kolkata, Bangalore & Mumbai).
Business Upturn
2 days ago
- Health
- Business Upturn
Dr. Lal PathLabs becomes first in India to adopt AI-based module for cancer lymph node metastasis detection
Dr. Lal PathLabs has taken a groundbreaking step in advancing cancer diagnostics in India by becoming the first laboratory in the country to introduce a deep learning-based AI module for the detection of lymph node metastasis, including micrometastasis. This innovation, developed in collaboration with Singapore-based healthtech company Qritive, was recently showcased at USCAP 2025, one of the most prestigious pathology conferences in the world. The accurate detection of cancer spread to lymph nodes is a critical factor in determining the stage and treatment strategy for patients. Missing these signs of cancer progression can allow the disease to advance, increasing the chances of it spreading to distant organs and reducing survival rates. The ability to identify even occult metastases in patients with early-stage cancer has the potential to significantly influence treatment plans and improve outcomes. Traditionally, detecting micrometastases—small clusters of cancer cells hidden in lymph nodes—has been a time-consuming and complex process, often requiring advanced testing. The new AI system, called QiAI Lymph Node Dx, addresses this challenge by using deep learning to analyze digital slides and identify cancer cells with exceptional precision. This integration of AI into diagnostic practice ensures that cancer detection becomes faster, more reliable, and highly accurate. What makes this development especially impactful is its ability to pick up even single cancer cells, which were later validated through immunohistochemistry testing. The AI model has been tested across various cancer types, including breast, colon, stomach, and esophageal cancers, consistently delivering highly accurate results. Breast cancer, which accounts for nearly 28% of cancer cases among women in India, particularly stands to benefit from this breakthrough, highlighting the clinical relevance of the technology. By achieving complete sensitivity and negative predictive value—meaning no metastatic cases went undetected—the AI system has proven to be a robust screening tool. Its tumor-agnostic design allows it to function effectively across different cancer types, making it a versatile solution for oncologists and pathologists alike. As cancer incidence continues to rise in India, the integration of advanced AI-powered diagnostic tools such as QiAI Lymph Node Dx is set to transform the landscape of cancer care. By enabling earlier and more accurate diagnoses, this technology not only improves the efficiency of medical practice but also ensures better treatment decisions, offering renewed hope to patients battling cancer. Ahmedabad Plane Crash
